Trial Profile

Letrozole Adjuvant Therapy Duration (LEAD) Study: Standard Versus Long Treatment. A Phase III Trial in Post-Menopausal Women With Early Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 21 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Letrozole (Primary)
Indications Early breast cancer
Focus Therapeutic Use
Acronyms GIM4; LEAD

Most Recent Events

17 May 2022 Planned End Date changed from 1 Aug 2022 to 1 Aug 2026.
15 Sep 2021 Primary endpoint (Disease-free survival) has been met as per results published in the Lancet Oncology
15 Sep 2021 Results of final analysis published in the Lancet Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com